These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11595692)

  • 21. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations.
    Lawrence JA; Adamson PC; Caruso R; Chow C; Kleiner D; Murphy RF; Venzon DJ; Shovlin M; Noone M; Merino M; Cowan KH; Kaiser M; O'Shaughnessy J; Zujewski J
    J Clin Oncol; 2001 May; 19(10):2754-63. PubMed ID: 11352969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
    ; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
    J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group.
    Patel R; Newman EM; Villacorte DG; Sato JK; Reaman GH; Finklestein JZ; Krailo MD; Hammond GD; Holcenberg JS
    Cancer Res; 1991 Sep; 51(18):4871-5. PubMed ID: 1893377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer.
    Cura JE; Blanzaco DP; Brisson C; Cura MA; Cabrol R; Larrateguy L; Mendez C; Sechi JC; Silveira JS; Theiller E; de Roodt AR; Vidal JC
    Clin Cancer Res; 2002 Apr; 8(4):1033-41. PubMed ID: 11948110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
    Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of 9-cis retinoic acid in adults with solid tumors.
    Kurie JM; Lee JS; Griffin T; Lippman SM; Drum P; Thomas MP; Weber C; Bader M; Massimini G; Hong WK
    Clin Cancer Res; 1996 Feb; 2(2):287-93. PubMed ID: 9816171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
    Marina NM; Cochrane D; Harney E; Zomorodi K; Blaney S; Winick N; Bernstein M; Link MP
    Clin Cancer Res; 2002 Feb; 8(2):413-8. PubMed ID: 11839657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193).
    Balis FM; Lange BJ; Packer RJ; Holcenberg JS; Ettinger LJ; Sallan SE; Heideman RL; Zimm S; Smithson WA; Cogliano-Shutta NA
    Cancer Res; 1985 Oct; 45(10):5169-72. PubMed ID: 4027992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
    Sutton LM; Warmuth MA; Petros WP; Winer EP
    Cancer Chemother Pharmacol; 1997; 40(4):335-41. PubMed ID: 9225952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
    Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study.
    Horton TM; Pati D; Plon SE; Thompson PA; Bomgaars LR; Adamson PC; Ingle AM; Wright J; Brockman AH; Paton M; Blaney SM
    Clin Cancer Res; 2007 Mar; 13(5):1516-22. PubMed ID: 17332297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
    Lau L; Supko JG; Blaney S; Hershon L; Seibel N; Krailo M; Qu W; Malkin D; Jimeno J; Bernstein M; Baruchel S
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):672-7. PubMed ID: 15701855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics.
    Conley BA; Egorin MJ; Sridhara R; Finley R; Hemady R; Wu S; Tait NS; Van Echo DA
    Cancer Chemother Pharmacol; 1997; 39(4):291-9. PubMed ID: 9025769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.